The messenger ribonucleic acid (mRNA) therapeutics contract development and manufacturing organization (CDMO) is a specialized service provider that supports pharmaceutical and biotechnology companies in the development, scale-up, and commercial manufacturing of mRNA-based medicines. These organizations offer integrated services such as mRNA synthesis, lipid nanoparticle (LNP) formulation, analytical testing, process optimization, and GMP-compliant production for clinical and commercial use. The primary purpose of an mRNA therapeutics CDMO is to enable fast, reliable, and high-quality production of mRNA-based drugs and vaccines without requiring companies to build in-house manufacturing facilities.
The global mRNA therapeutics CDMO market was valued at $2,458.8 million in 2020 which grew till 2025 at a compound annual growth rate (CAGR) of more than 13.0%.
High Manufacturing Costs
High manufacturing costs hindered the growth of the mRNA therapeutics CDMO market in the historic period. Producing mRNA therapies requires expensive raw materials, advanced bioprocessing equipment, strict contamination controls, and highly skilled technical personnel. In addition, complex formulation processes, cold-chain storage, and rigorous quality testing further increased operational expenses. For many biotech and pharmaceutical companies, these high costs reduced the economic attractiveness of outsourcing or slowed the progression of candidates into later development stages. CDMOs also faced substantial capital investments to build compliant facilities and expand capacity. As a result, profitability pressures and budget constraints restrained market expansion despite growing scientific interest in mRNA-based therapeutics. For instance, according to the Merck & Co., Inc., a US-based pharmaceutical company, reported that material costs account for only about 23% of total expenses for inactivated vaccines, compared with roughly 81% for mRNA vaccines, highlighting the significantly higher cost structure of mRNA production. Most mRNA vaccine costs stem from daily operational materials, particularly during plasmid linearization, transcription, and enzymatic reaction stages, which are the most expensive steps in the process. Therefore, high manufacturing costs hindered the growth of the mRNA therapeutics CDMO market.
Industry 4.0 And Intelligent Manufacturing
Major companies operating in the mRNA therapeutics CDMO market are focusing on automating and accelerating plasmid DNA production to improve efficiency, reduce contamination risk, and support rapid development of mRNA vaccines and gene therapies. Industry 4.0 and intelligent manufacturing are increasingly critical to advancing the mRNA therapeutics CDMO landscape by enabling smarter, more efficient, and highly controlled production processes that overcome many historical manufacturing challenges. Traditional mRNA manufacturing involves complex steps such as in-vitro transcription, enzymatic reactions, sterile processing, lipid nanoparticle (LNP) formulation, and stringent quality testing, all of which demand precision, reproducibility, and stringent regulatory compliance. Integrating Industry 4.0 technologies-such as real-time data analytics, advanced sensors, machine learning, digital twins, and automated process control-enhances visibility and control across these workflows, reducing variability and improving yield.
The global mRNA therapeutics CDMO market is fairly concentrated, with large players operating in the market. The top 10 competitors in the market made up 36.7% of the total market in 2024.
mRNA Therapeutics CDMO Global Market Opportunities And Strategies To 2035 from The Business Research Company provides the strategists; marketers and senior management with the critical information they need to assess the global mRNA therapeutics CDMO market as it emerges from the COVID-19 shut down.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market research findings.
- Benchmark performance against key competitors.
- Utilize the relationships between key data sets for superior strategizing.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis.
Where is the largest and fastest-growing market for mRNA therapeutics CDMO? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The mRNA therapeutics CDMO market global report from The Business Research Company answers all these questions and many more.
The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market's history and forecasts market growth by geography. It places the market within the context of the wider mRNA therapeutics CDMO market; and compares it with other markets.
The report covers the following chapters
- Introduction And Market Characteristics- Brief introduction to the segmentations covered in the market, definitions and explanations about the segments, key products, supply chain and market attractiveness scoring and analysis.
- Key Trends- Highlights the major trends shaping the global market. This section also highlights likely future technologies and developments in the market.
- Growth Analysis And Strategic Analysis- Framework Analysis on PESTEL, end use industries, market growth rate, global historic (2020-2025) and forecast (2025-2030, 2035F) market values and drivers and restraints that support and control the growth of the market in the historic and forecast periods, forecast growth contributors and total addressable market (TAM).
- Regional And Country Analysis- Historic (2020-2025) and forecast (2025-2030, 2035F) market values and growth and market share comparison by region and country.
- Market Segmentation- Contains the market values (2020-2025) (2025-2030, 2035F) and analysis for each segment by type of service, by indication, by application and by end user in the market. Historic (2020-2025) and forecast (2025-2030) and (2030-2035) market values and growth and market share comparison by region market.
- Regional Market Size And Growth- Regional market size (2025), historic (2020-2025) and forecast (2025-2030, 2035F) market values and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa and major countries within each region.
- Competitive Landscape- Details on the competitive landscape of the market, estimated market shares and company profiles of the leading players.
- Competitive Benchmarking- Briefs on the financials comparison between major players in the market.
- Competitive Dashboard- Briefs on competitive dashboard of major players.
- Key Mergers And Acquisitions- Information on recent mergers and acquisitions in the market covered in the report. This section gives key financial details of mergers and acquisitions, which have shaped the market in recent years.
- Recent Developments- Information on recent developments in the market covered in the report.
- Other Major And Innovative Companies- Details on the startups, company profiles of other major and innovative companies in the market.
- Market Opportunities And Strategies- Describes market opportunities and strategies based on findings of the research, with information on growth opportunities across countries, segments and strategies to be followed in those markets.
- Conclusions And Recommendations- This section includes recommendations for mRNA Therapeutics CDMO providers in terms of product/service offerings geographic expansion, marketing strategies and target groups
- Appendix This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report.
Markets Covered:
- 1) By Type Of Service: Development Services; Manufacturing Services; Laboratory Services
- 2) By Indication: Infectious Diseases; Metabolic And Genetic Diseases; Cardiovascular And Cerebrovascular Diseases; Oncology; Other Indications
- 3) By Application: Viral Vaccines; Protein Replacement Therapies; Cancer Immunotherapies
- 4) By End-User: Pharmaceutical Companies; Biotechnology Companies; Academic Institutions; Research Organizations
- Companies Mentioned: Lonza Group; Thermo Fisher Scientific Inc. (Patheon); Samsung Biologics Co. Ltd.; Wuxi Biologics (WuXi Vaccines); Catalent, Inc. (Catalent Biologics Inc.)
- Countries: China; Australia; India; Indonesia; Japan; South Korea; Taiwan; USA; Canada; Brazil; France; Germany; UK; Italy; Spain; Russia
- Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time-series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets; GDP proportions; expenditure per capita; mRNA therapeutics CDMO indicators comparison.
- Data segmentations: country and regional historic and forecast data; market share of competitors; market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.